Optimizing infliximab for inflammatory bowel disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) with Crohn's disease, ulcerative colitis, or inflammatory bowel disease that is not classified.
- You are in the hospital with a moderate-to-severe flare that did not improve with steroids given through a vein (IV).
- Your doctor has already decided to start you on infliximab (a biologic medicine) as part of your standard care.
- You do not have an uncontrolled infection.
- You do not have a permanent ileostomy (a stoma for waste) or an ileal pouch-anal anastomosis (J-pouch).
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how patients with Crohn's disease or ulcerative colitis respond to infliximab (a biologic medication) given as injections under the skin after an initial IV dose. Researchers want to understand which patients benefit most and for how long.
This study tests whether giving a steroid (dexamethasone) before an infliximab infusion can prevent allergic reactions in people with moderate-to-severe Crohn's disease or ulcerative colitis. If you qualify, you will receive either the steroid or a placebo before your infliximab treatment.
This study monitors levels of certain medications (infliximab, adalimumab, vedolizumab, ustekinumab) in children with inflammatory bowel disease to see if adjusting the dose helps them feel better. It aims to improve treatment outcomes.
This study tests if a special diet (called CDED) combined with infliximab (a biologic drug) is more effective than infliximab alone for children with newly diagnosed or relapsed moderate-to-severe Crohn’s disease. It aims to improve gut healing and reduce inflammation.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
Hear when a new Inflammatory Bowel Disease (IBD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.